Alzheimer's Disease biological PET staging using plasma 1 p217+tau 2

3

4 Azadeh Feizpour^{1,2}, Vincent Doré^{2,3}, Natasha Krishnadas^{1,2}, Pierrick Bourgeat⁴, James D. Doecke^{4,5}, Ziad S. Saad⁶, Gallen Triana-Baltzer⁶, Simon M. Laws^{5,7,8}, Rosita Shishegar^{3,9}, Kun 5 6 Huang², Christopher Fowler¹, Larry Ward¹, Colin L. Masters¹, Jurgen Fripp⁴, Hartmuth C.

- 7 Kolb⁶, Victor L. Villemagne^{2,10}, Christopher C. Rowe^{1,2,11,*}
- , 8 9
- 10 1 The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, 11 Victoria, Australia;
- 12 2 Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia;
- 13 3 The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia;
- 14 4 The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia;
- 15 5 Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia;
- 16 6 Neuroscience Biomarkers, Janssen Research and Development, La Jolla, CA, USA;
- 17 7 Collaborative Genomics and Translation Group, Edith Cowan University, Joondalup, Western
- 18 Australia, Australia;
- 19 8 Curtin Medical School, Curtin University, Bentley, Western Australia, Australia;
- 20 9 School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash
- 21 University, Melbourne, Victoria, Australia;
- 22 10 Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA;
- 23 11 Florey Department of Neuroscience and Mental Health, The University of Melbourne, Melbourne,
- 24 Victoria, Australia.
- 25
- 26
- 27 *Address correspondence to: Professor Christopher C Rowe, Department of Molecular Imaging &
- Therapy, Austin Health, 145 Studley Road, Heidelberg, VIC. 3084, Australia. Telephone: +61-3-9496 28
- 29 3321. Fax +61-3-9458 5023.
- 30 Email: christopher.rowe@austin.org.au

Background: Plasma phospho-tau biomarkers, such as p217+tau, excel at identifying

31 Abstract

32

33 Alzheimer's Disease (AD) neuropathology. However, questions remain regarding their 34 capacity to inform AD biological PET stages at group level and maintain the same precision at individual patient level. 35 Method: Participants included 248 cognitively unimpaired (CU) and 227 cognitively 36 impaired (CI) individuals, with Janssen plasma p217+tau Simoa® assay, ¹⁸F-NAV4694 Aβ 37 PET (A) and ¹⁸F-MK6240 tau PET (T) data. Biological PET stages were defined based on the 38 39 draft NIA-AA Revised Criteria (July 2023): Initial (A+T-), Early (A+T_{MTL}+), Intermediate 40 (A+T_{MOD}+), and Advanced (A+T_{HIGH}+). We used thresholds for A+ of 25 Centiloid and for 41 Thigh of 80 Centaur (2.68 SUVR_{temporo-parietal}). Adding an A-T- stage for comparison, we 42 assessed the performance of p217+tau in discriminating between these stages at the group 43 level using Receiver Operating Characteristic (ROC) analysis and at the individual level using logistic regression. 44 45 **Results:** Plasma p217+tau concentrations increased across the stages, with significant differences between them, except for the Initial and Early stages. Screening for Advanced (vs. 46 47 lower stages), combined Intermediate/Advanced (vs. lower stages), or all stages (vs. A-T-), 48 p217+tau showed good group-level discriminations (AUC 0.91, 0.92 and 0.92; CI only: AUC 49 0.83, 0.89, 0.93, respectively). At the individual level, the likelihood of PET stage vs. 50 p217+tau level showed good discrimination of A-T- vs any A+ stage and of combined 51 Intermediate/Advanced disease stage vs lower stages in the CI. 52 **Conclusion**: In addition to accurately screening for A+ individuals, plasma p217+tau shows 53 promise for separating persons with either Intermediate or Advanced stage AD from those at 54 a lower stage, providing prognostic information and informing better selection for trials and 55 disease modifying therapies.

56 Introduction

- 57 The *in vivo* staging of Alzheimer's disease (AD) has become increasingly important,
- 58 particularly in light of the recent breakthroughs in disease-modifying therapies for AD¹.
- 59 Positron Emission Tomography (PET) imaging allows *in vivo* staging however, the cost and
- 60 limited scalability underscores the need to assess plasma biomarkers for this purpose. Among
- a range of plasma biomarkers, measures of phosphorylated tau (p-tau) at amino acid 217 (p-
- 62 tau217) have demonstrated significant potential, rivalling the gold-standards of amyloid-beta
- 63 (Ab) PET and cerebrospinal fluid (CSF) 2 .
- 64 The plasma "p217+tau" assay is a high sensitivity Simoa assay using a capture antibody
- 65 (pT3), raised against tau paired helical filaments (PHF), that binds to phosphorylation at
- 66 aa217 (p217) with enhanced binding when other nearby phosphorylated sites are present,
- 67 predominantly at aa212. It has shown a similar performance to p-tau217 in detecting $A\beta$
- 68 status in CSF, distinguishing clinical diagnostic groups and predicting progression from Mild
- 69 Cognitive Impairment (MCI) to AD³. A comparison of its performance to recent-generation
- 70 PET tracers has demonstrated similarly good diagnostic accuracy ⁴. Furthermore, we have
- 71 previously shown that p217+tau predicted cognitive decline and if used as a pre-screening
- tool in pre-clinical AD trials or screening tool in MCI/AD trials, substantial cost reduction
- 73 could be achieved ⁵. While accumulating evidence underscores the excellent diagnostic,
- 74 prognostic, and clinical trial utility of plasma p-tau biomarkers, their performance in disease
- 75 staging is at present understudied. Disease staging needs to be assessed at both group level
- 76 and individual level. Group-level analysis establishes receiver operating characteristic
- (ROC)-based thresholds (such as 90% sensitivity or 90% positive predictive value (PPV)
- thresholds) that have proven useful in enriching clinical trial populations. Individual-level
- analysis provides the foundation for development of risk assessment models aimed at the
- 80 identification of individuals at elevated risk for specific stages of AD to tailor their prognosis
- 81 and treatment.
- 82 A recent report by Jack *et al.* ⁶ examined whether p-tau217 could discriminate between AD
- 83 disease stages. They defined four tau PET topographic stages using Braak-like PET staging
- 84 schemes ^{7, 8} and group-level results indicated a good discrimination between Braak 0 and
- 85 Braak 1-6 stages in the cognitively unimpaired participants.
- 86 In the present study, we were interested in both individual-level and group-level
- 87 discrimination of disease stages. Therefore, we employed the biological PET staging of AD,
- 88 recently proposed by draft NIA-AA Revised Diagnosis and Staging Criteria (2023) ⁹ and

- 89 aimed to assess the ability of plasma p217+tau to discriminate individuals that fall within
- these stages. 90

91 Methods

92 Participants

From AIBL and ADNeT cohorts, 475 participants with ¹⁸F-MK6240 tau PET, ¹⁸F-NAV4694 93 94 A β PET and plasma p217+tau were selected. Details of cohort recruitment and evaluation are described elsewhere ¹⁰. Briefly, all participants were clinically classified as cognitively 95 96 unimpaired (CU), or participants with mild cognitive impairment (MCI), Alzheimer's disease 97 (AD) dementia or non-AD dementia, by a multi-disciplinary panel blind to PET imaging and 98 blood assays results. The MCI and dementia groups were combined into a cognitively impaired (CI) group for some analyses. A diagnosis of CU required performance within 1.5 99 100 standard deviations (SD) of the published norms for their age group on selected 101 neuropsychological assessments. A diagnosis of MCI or AD dementia followed the 102 internationally agreed clinical criteria^{11, 12}. Approval was obtained from institutional ethics 103 review committees for the AIBL and ADNeT studies and written informed consent was 104 obtained from all participants.

105 PET Image Acquisition and Analysis

106 Aβ PET imaging involved a 20-minute acquisition, performed 50 minutes after injection of 107 200 MBq of ¹⁸F-NAV4694 intravenously. Tau PET imaging was conducted on a separate 108 day, with a 20-minute acquisition, performed 90 minutes after intravenous administration of 185 MBq of ¹⁸F-MK6240. For Aβ PET scans, spatial normalization was achieved using 109 CapAIBL¹³ and the results were standardised using the Centiloid (CL) scale^{14, 15}. For tau 110 111 PET scans, spatial normalization was performed using the MR-less CapAIBL PCA-based 112 method ¹⁶. Tau PET scans were scaled using the cerebellar cortex as the reference region. ¹⁸F-113 MK6240 standardized uptake value ratio (SUVR) was estimated for three in-house composite 114 regions of interest (ROI): 1) mesial temporal (Me) ROI, comprising entorhinal cortex, 115 amygdala, hippocampus, and parahippocampus, 2) temporoparietal (Te) ROI, consisting of inferior temporal, fusiform, supramarginal and angular gyri, posterior cingulate/ precuneus, 116 117 superior and inferior parietal, and lateral occipital cortex and 3) rest of neocortex (R) 118 including dorsolateral and ventrolateral prefrontal, orbitofrontal, gyrus rectus, superior and middle temporal, and anterior cingulate ¹⁷. A CL threshold of 25 was selected to discriminate 119 120 A β positive (A+) vs. A β negative (A-) PET scans. Previously reported thresholds based on 121 the 95th percentile of A- CU were used to discriminate tau positive (T+) from tau negative (T-) PET scans-1.18 SUVR for Me, 1.24 SUVR for Te and 1.08 SUVR for R¹⁸. For tau PET 122

- 123 uptake in the moderate SUVR range in the Te ROI, we considered values between 1.24 and
- 124 2.68. The upper threshold of 2.68 Te SUVR corresponds to 80 CenTauR^{19, 20}. We considered
- 125 80 CenTauR as a cut-off point between low/medium (or intermediate) and high tau burden, as
- 126 we calculated that this approximates the threshold used for tau PET staging (intermediate *vs*.
- 127 high) in the Trailblazer-Alz 2 randomized clinical trial ¹.

128 Plasma p217+tau Assay

- 129 Fasting blood was collected 2.4 ± 10.4 months from the time of A β PET scan and 0.1 ± 4.2
- 130 months from the tau PET scan. Plasma from K2-EDTA tubes (7.5 mL S-monovette
- 131 01.1605.008, Sarstedt), containing prostaglandin E1 (33 ng/mL of whole blood, Sapphire
- 132 Biosciences), was centrifuged at room temperature for 10 mins at 200g to collect platelet-rich
- 133 plasma. Then, to provide plasma that was snap frozen within 2 hr of collection, it was
- 134 centrifuged at 800g for 10 mins, following which it was stored in vapour phase liquid
- 135 nitrogen prior to shipping on dry ice from Australia to Janssen R&D, La Jolla, CA, USA. The
- 136 plasma p217+tau assay was completed on a Single Molecule Array (Simoa®) HD-X
- 137 platform, blinded to all subject data. The technique has been previously described by Triana-
- 138 Baltzer *et al.*²¹. Plasma p217+tau assay results from two laboratories, Janssen R&D (cohort
- 139 1; n=397) and Quanterix Corp, MA, USA (cohort 2; n=317), were combined. This study
- 140 included all participants from cohort 2, and those unique to cohort 1 who were not already
- 141 part of cohort 2 (final n=506). Assay scales measured from both laboratories were
- 142 comparable.

143 Implementation of 2023 Proposed NIA-AA Staging of AD with PET:

- 144 In the draft NIA-AA Revised Diagnostic and Staging Criteria (2023)⁹, the following
- 145 biological PET staging scheme is proposed: 1. Initial stage: proposed as abnormal Aβ with no
- 146 tau uptake (A+T-), 2. Early stage: as abnormal A β with tau uptake limited to medial temporal
- 147 region (A+T_{MTL}+), 3. Intermediate stage: as abnormal A β with moderate tau uptake in a
- 148 neocortical ROI (A+T_{MOD}+), and 4. Advanced stage: as abnormal A β with high tau uptake in
- 149 the same neocortical region (A+T_{HIGH}+). For stages 3 and 4, we considered Te as our
- 150 neocortical ROI. Table 1 displays our selected CL and SUVR cut-offs and ranges for defining
- 151 the aforementioned stages:
- 152
- 153
- 154 Table 1. Biological PET staging

PET stages	Centiloid	Tau (SUVR)		
		Me	Те	R
Initial: A+T-	≥25	< 1.18	< 1.24	< 1.08
Early: A+T _{MTL} +	≥25	≥1.18	< 1.24	< 1.08
Intermediate: A+T _{MOD} +	≥25	$< \text{or} \ge 1.18$	Between 1.24 & 2.68	
Advanced: A+T _{HIGH} +	≥25	$< \text{or} \ge 1.18$	≥2.68	

155 In addition, we considered an A-T- group, to allow comparison:

A-T-	< 25	< 1.18	< 1.24	< 1.08

156 SUVR standardized uptake value ratio; Me mesial temporal ROI; Te temporoparietal ROI; 157 R rest of neocortex ROI.

158 Of the 506 participants with available plasma p217+tau assay results, 31 who were A- but T+

in one or all three ROIs did not fit within any of the above AT categories and were excluded 159

160 from subsequent analyses. Among these, 11 had mildly elevated MTL binding and were

postulated to have primary age related tauopathy (PART) but 9 were positive on 161

162 quantification in MTL and temporo-parietal. This proportion of the total study sample of $\sim 2\%$

as having clearly positive neocortical tau PET but negative amyloid PET is consistent with 163

164 our previous report ²² (see Supplementary Table 1 for demographic characteristics of the

165 excluded participants).

166 **Statistical Methods**

167 All statistical analyses were completed using Python version 3.9.13, unless otherwise

168 specified. Demographic differences between groups were assessed using one-way ANOVA

169 for continuous data and Pearson's χ^2 test of independence for categorical variables (gender,

170 Apolipoprotein E (APOE) E4 status, clinical diagnosis). Pairwise comparisons for continuous

171 data were performed using Tukey Honest Significant Difference (HSD) test while categorical

172 variables were analysed with Pearson's χ^2 test. Bonferroni correction was applied to all

173 multiple pairwise comparisons. To investigate the magnitude of differences in plasma

174 p217+tau concentration across the PET stages, effect sizes were estimated using Cohen's d.

175 ROC analysis was used to assess group-level discriminatory capability. The area under the

ROC curve (AUC) from each comparison was used to assess the performance of p217+tau 176

177 alone or in combination with other predictors (age, gender and APOE ε 4 status) in

178 discriminating different PET stages. The AUCs were compared using DeLong test (R version

179 4.2.3). Specificity, sensitivity, PPV and negative predictive value (NPV) were reported with

180 bootstrapped 95% confidence intervals (shown in square brackets). PPV and NPV were not

- 181 adjusted for disease prevalence. Optimal p217+tau thresholds for discriminating between the biological PET stages were derived using Youden's Index. 182
- 183 Given that there were only nine participants with p217+tau values above 500 fg/ml, with a
- 184 range from 507 to 902 fg/ml (6 of whom were A+T_{HIGH}+ and 3 were A+T_{MOD}+) and
- 185 considering the limited statistical power to estimate the line of best fit, we restricted our
- 186 regression analyses to plasma p217+tau concentrations between 0 and 500 fg/ml in the
- 187 subsequent sections. To evaluate the probability of a participant belonging to a distinct PET
- stage (individual patient-level staging), we employed two methods. In the first approach, we 188
- 189 computed probability scores by applying a binary logistic regression model. In this model, we
- 190 used plasma p217+tau as the predictor (independent variable) and grouped PET stages as the
- 191 outcome (dependent variable), where the stages were categorized into binary groups of 0 and
- 192 1. Then, we compared the results of the logistic regression to the second approach, a sliding
- window method. Here, we calculated PET stage probabilities within sequential bands of 193
- 194 plasma p217+tau concentrations, with each band spanning 80 fg/ml. We selected an 80 fg/ml
- 195 band width as a balance between achieving overly smoothed curves and avoiding excessive
- 196 noise. The calculated probability for each band was centred at the midpoint of the p217+tau
- 197 concentration range. The probability estimates from both methods were plotted against
- 198 p217+tau concentrations and compared across the biological PET stages.

Results 199

200 Participant demographics

- 201 Demographic characteristics of the participants are presented in Table 2. Participants
- 202 included 248 CU, 144 with MCI and 83 with dementia (total n = 475). Among these, 192
- 203 were categorized as A-T-, 80 as A+T-, 31 as A+T_{MTL}+, 128 as A+T_{MOD}+, and 44 as
- 204 A+T_{HIGH}+. The A+T_{HIGH}+ group had a younger average age and lower level of education
- 205 compared to the other groups. No significant gender differences were observed among the
- 206 groups. Relative to A-T-, all other groups displayed higher rates of APOE E4 carriership and
- 207 greater prevalence of MCI or dementia diagnosis. These groups also exhibited higher
- 208 Centiloid values and plasma p217+tau concentrations. The A+T_{MOD}+ and A+T_{HIGH}+ had
- 209 lower MMSE scores, and A+T-, A+T_{MOD}+, and A+T_{HIGH}+ had higher CDR-SoB scores. For
- 210 a breakdown of participant demographics by clinical diagnosis, see Supplementary Table 2.
- 211 Table 2. Demographic characteristics

	A-T-	A+T-	A+T _{MTL} +	A+Tmod+	A+Thigh+	р
n	192	80	31	128	44	
Age (years)	74.1 ± 6.2	76.0 ± 7.2	75.2 ± 8.4	75.5 ± 7.1	68.3 ± 7.8 ***	< 0.001
Education (years)	13.7 ± 3.1	12.9 ± 3.4	12.9 ± 2.7	12.6 ± 2.8	12.1 ± 2.8	0.013
Gender, F (%)	50.00%	42.50%	45.20%	53.90%	50.00%	0.589
<i>APOE</i> ε4 (%)	21.10%	50.60% ***	74.20% ***	68.50% ***	62.80% ***	< 0.001
MMSE	28.4 ± 1.7	27.4 ± 2.3	26.8 ± 2.8	$\begin{array}{c} 25.0\pm4.1\\ ***\end{array}$	$\begin{array}{c} 21.7\pm5.9\\ ***\end{array}$	< 0.001
CDR_SoB	0.4 ± 1.1	1.5 ± 2.7 **	1.6 ± 1.8	$\begin{array}{c} 2.6 \pm 2.9 \\ *** \end{array}$	4.8 ± 3.3 ***	< 0.001
Centiloid (CL)	0.8 ± 7.4	75.6 ± 39.1***	91.6 ± 39.0***	$119.6 \pm 41.0 \\ ***$	122.2 ± 32.2***	< 0.001
Tau PET, Me (SUVR)	0.9 ± 0.1	0.9 ± 0.1	1.4 ± 0.2	$\begin{array}{c} 1.8 \pm 0.4 \\ *** \end{array}$	2.3 ± 0.6	< 0.001
Tau PET, Te (SUVR)	1.0 ± 0.1	1.0 ± 0.1	1.1 ± 0.1	$\begin{array}{c} 1.8 \pm 0.4 \\ *** \end{array}$	3.6 ± 0.9	< 0.001
Plasma p217+tau (fg/ml)	69.5 ± 36.7	127.0 ± 54.1 ***	147.8 ± 51.8 ***	227.9 ± 98.2 ***	363.2 ± 163.3 ***	<0.001
MCI or Dementia (%)	18.80%	40.00% ***	54.80% ***	78.10% ***	95.50% ***	< 0.001

212 Values presented as mean ± SD for all variables except n, Gender, Apolipoprotein E

213 (APOE) E4 and MCI or Dementia (%). SD Standard deviation; MMSE mini-mental state

214 examination; CDR-SB clinical dementia rating sum of boxes; MCI Mild Cognitive

216 multiple comparisons).

²¹⁵ Impairment. * p < 0.05, ** p < 0.01, *** p < 0.001 for comparison to A-T- (corrected for

217 Plasma p217+tau concentration by PET stages

- 218 The median concentration of plasma p217+tau exhibited a clear incremental trend across the
- stages, with values of 63.5 fg/ml in the A-T-, 118.7 fg/ml in A+T-, 140.7 fg/ml in A+T_{MTL}+,
- 220 211.0 fg/ml in A+T_{MOD}+ and 336.7 fg/ml in A+T_{HIGH}+ (Figure 1). A pairwise comparison—
- 221 corrected for multiple comparisons— revealed significant differences in mean plasma
- 222 p217+tau concentration between all stages, except for the comparison between A+T- and
- 223 A+T_{MTL}+. Henceforth, in all subsequent analyses, these two stages were consolidated into a
- 224 unified stage referred to as Initial/Early (A+T_{None/MTL}). For detailed information on Cohen's *d*
- effect sizes and *p*-values for comparison between the stages, see Supplementary Table 3.



226

227 Figure 1. Plasma p217+tau levels in the different PET stages. The error bars in the 228 boxplots represent 1.5 times the interquartile range (IQR) above and below the upper (75th 229 percentile) and lower (25th percentile) quartiles. Plasma p217+tau concentrations exhibited 230 a clear incremental trend across these stages, with significant differences between all, 231 except for the Initial and Early stages. A-T- amyloid negative and tau negative; A+T-232 amyloid positive and tau negative; $A + T_{MTL}$ + amyloid positive with tau uptake limited to 233 medial temporal region; $A + T_{MOD}$ + amyloid positive with moderate tau uptake in temporo-234 parietal region; $A + T_{HIGH}$ + amyloid positive with high tau uptake in temporo-parietal 235 region. *** p < 0.001 (corrected for multiple comparisons); ns non-significant.

236 Group-level approach for disease staging

237 Discrimination between A-T- and A+ stages

- In a clinical trial investigating the effect of a disease-modifying treatment on all biological
- 239 PET stages of AD, discriminating between those stages and A-T- would be important.
- 240 Our findings showed that when CU and CI participants were combined, plasma p217+tau
- alone discriminated between A-T- and all stages combined of A+, with an AUC of 0.92

- 242 (Figure 2A), significantly better than the discrimination by the base model which included 243 age, gender and APOE ɛ4 status (AUC: 0.75, p<0.001). The Youden index provided a 244 threshold concentration of 99.4 fg/ml [89.7 - 102.4 fg/ml], which yielded sensitivity of 0.87 245 [0.83 - 0.91], specificity of 0.84 [0.78 - 0.88], PPV of 0.89 [0.85 - 0.92] and NPV of 0.81 246 [0.77 - 0.87] (Supplementary Table 4). Adding age or gender separately did not improve the AUC of the model with p217+tau while APOE ɛ4 status improved the model slightly (AUC: 247 248 0.94, p < 0.05). The full model including p217+tau, age, gender and APOE ε 4 status yielded the highest AUC (0.94, *p*<0.01 compared to model with p217+tau only). 249 250 Among CI only participants, plasma p217+tau discriminated between A-T- and A+ 251 individuals with an AUC of 0.93 (Figure 2D), significantly better than the discrimination by 252 the base model (AUC: 0.82, p < 0.05). Youden threshold of 126.7 fg/ml [94.8 - 149.9 fg/ml] 253 gave a sensitivity of 0.83 [0.69 - 0.95], specificity of 0.86 [0.79 - 1.0], PPV of 0.97 [0.96 -254 1.0], and NPV of 0.48 [0.34 - 0.74] (Supplementary Table 5). Adding age, gender or APOE
- ε4 status separately did not improve the model with p217+tau. However, adding all predictors 255
- 256 together (full model) had the highest AUC (0.96, p<0.05 compared to model with p217+tau 257 only).
- 258 Discrimination between combined $A-T-/A+T_{None/MTL}$ and combined $A+T_{MOD}+/A+T_{HIGH}+$
- 259 In a clinical trial assessing the impact of a disease-modifying treatment on individuals with
- 260 Aβ and intermediate or high neocortical tau pathology, screening for these individuals vs. A-
- 261 T-/A+T_{None/MTL} individuals becomes a crucial consideration.
- 262 Among the CU & CI combined, for discriminating these two groups, using p217+tau alone,
- the AUC was 0.92 (Figure 2B), performing significantly better than the base model (AUC: 263
- 264 0.69, p < 0.001). Youden index gave a threshold of 168.0 fg/ml [131.8 - 177.4 fg/ml] which
- vielded a sensitivity of 0.77 [0.73 0.90], specificity of 0.91 [0.80 0.95], PPV of 0.84 [0.71 265
- 0.89], and NPV of 0.88 [0.85 0.93] (Supplementary Table 4). Adding age, gender or 266
- APOE E4 status separately or together did not improve the AUC of the model with p217+tau. 267
- Among the CI only, the AUC was 0.89 (Figure 2E), significantly better than the 268
- discrimination by the base model (AUC: 0.65, p<0.001), Youden threshold 177.4 fg/ml 269
- 270 [168.0 - 179.4 fg/ml], sensitivity 0.78 [0.74 - 0.86], specificity 0.92 [0.85 - 0.96], PPV 0.94
- 271 [0.89 - 0.97], NPV 0.72 [0.66 - 0.81] (Supplementary Table 5). Adding age, gender or APOE
- 272 ε4 status separately or together did not improve the model with p217+tau.

- 273 Discrimination between combined A-T-/A+ $T_{None/MTL}/A+T_{MOD}+$ and A+ $T_{HIGH}+$
- 274 In a therapeutic trial evaluating the effect of an intervention in the Advanced (high
- 275 neocortical tau) group only, or wishing to exclude those with Advanced tau, discrimination
- 276 between A-T-/A+T_{None/MTL}/A+T_{MOD}+ and A+T_{HIGH}+ will be crucial.
- 277 Among the CU & CI combined, the use of plasma p217+tau alone for discriminating between
- 278 these two groups gave an AUC of 0.91 (Figure 2C), significantly better than the
- 279 discriminatory performance of the base model (AUC: 0.75, p<0.01). Youden index yielded a
- 280 threshold of 205.4 fg/ml [173.2 - 257.9 fg/ml] with a sensitivity of 0.89 [0.79 - 0.97],
- 281 specificity of 0.82 [0.75 - 0.90], PPV of 0.33 [0.25 - 0.47], NPV of 0.99 [0.98 - 1.0]
- 282 (Supplementary Table 4). Adding age, gender or APOE ɛ4 status separately or together did
- 283 not improve the model with p217+tau.
- 284 When only CI participants were included, plasma p217+tau alone discriminated between
- 285 these two groups with an AUC of 0.84 (Figure 2F) and this AUC did not significantly differ
- from any of the other models. Youden index provided a threshold of 230.3 fg/ml [205.4 -286
- 287 299.5 fg/ml] giving sensitivity of 0.84 [0.69 - 0.95], and specificity 0.71 [0.64 - 0.88]
- 288 (Supplementary Table 5). With PPV of 0.39 [0.31 - 0.58] and NPV of 0.95 [0.92 - 0.98],
- 289 p217+tau effectively excluded Advanced stage AD when less than the Youden threshold but
- 290 did not accurately predict Advanced stage when above, predominantly due to the presence of
- 291 many Intermediate stage AD participants with p217+tau above the threshold.
- 292 For a pairwise comparison of each two biological PET stages, see Supplementary Table 6.

medRxiv preprint doi: https://doi.org/10.1101/2024.01.11.24301180; this version posted January 13, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-ND 4.0 International license .



293

294 Figure 2. ROC analysis for group-level PET staging, CU and CI combined (Top panel), and 295 CI only (Bottom panel). Base model includes age, gender, and Apolipoprotein E (APOE) 296 ϵ 4 status. Full model includes p217+tau, age, gender, and APOE ϵ 4 status. pT217 plasma 297 p217+tau; AUC area under the receiver operating characteristic curve. A-T- amyloid 298 negative and tau negative; $A + T_{None/MTL}$ amyloid positive and tau negative or amyloid 299 positive with tau uptake limited to medial temporal region; $A + T_{MOD}$ + amyloid positive 300 with moderate tau uptake in temporo-parietal region; $A + T_{HIGH}$ + amyloid positive with high tau uptake in temporo-parietal region. *p<0.05, **p<0.01, ***p<0.001 for comparison of 301 302 the model with p217+tau only, to the base model (corrected for multiple comparisons). 303 p < 0.05, p < 0.01, for comparison of models with additional predictors to the model with 304 p217+tau only (after correction for multiple comparisons).

305 Discrimination between disease stages of enrolled participants

- 306 In the preceding sections, we demonstrated that employing a Youden threshold of 177.4
- 307 fg/ml allowed screening for CI participants who were either A+T_{MOD}+ or A+T_{HIGH}+, with a
- 308 PPV of 0.94. In some therapeutic trials, it might be essential to stage enrolled participants for
- 309 analytical purposes. For instance, one may wish to assess the impact of an intervention only
- 310 in participants with high neocortical tau ($A+T_{HIGH}+$). This led us to enquire whether, in the

- 311 absence of A β and tau PET imaging, p217+tau could discriminate between A+T_{HIGH}+ and
- those at lower stages in participants with p217+tau values above 177.4 fg/ml ($pT_{177.4+}$).
- 313 Among the $pT_{177.4}$ + participants, for discriminating between the A+T_{HIGH}+ and the lower
- stages, the AUC was 0.76 [0.68 0.83], Youden index threshold 299.5 fg/ml [257.9 402.9],
- sensitivity 0.71 [0.47 0.91], specificity 0.70 [0.52 0.95], PPV 0.52 [0.41 0.79], NPV 0.84
- 316 [0.76 0.93]. This indicates that this threshold could be potentially used to rule out
- 317 A+T_{HIGH}+, among the $pT_{177.4}$ + participants.
- 318 Individual-level approach for disease staging
- 319 We also performed logistic regressions to ascertain whether an individual's plasma p217+tau
- 320 level can inform their classification into A-T-, Initial-Early (A+T_{None/MTL}), Intermediate
- 321 (A+T_{MOD}+), or Advanced (A+T_{HIGH}+) stages. Figure 3 (left: CU & CI combined; right: CI
- 322 only) displays the logistic regression probability scores for each stage as a function of plasma
- 323 p217+tau concentrations. At any given plasma p217+tau value, an individual is most likely to
- belong to the stage with the highest probability score. Individuals with low p217+tau
- 325 concentrations (below 110 fg/ml for CU & CI combined, or 93 fg/ml for CI only) had the
- 326 highest likelihood of being A-T-. A+T_{None/MTL} was the classification with the highest
- 327 likelihood in p217+tau value range of 110-172 fg/ml for CU & CI combined, and 93-150
- 328 fg/ml for CI only. A+T_{MOD}+ was the most likely classification for a wide range of moderate
- 329 p217+tau values (172-375 fg/ml for CU & CI combined, and 150-374 fg/ml for CI only). For
- 330 p217+tau values higher than ~375 fg/ml, the classification of A+T_{HIGH}+ was the most likely.
- 331 In Figure 3, the likelihoods from logistic regression (solid line) are compared to the ones
- 332 estimated using the sliding window method (dots), indicating good concordance between the
- 333 two approaches in computing probabilities.
- 334
- 335



336



338 CU & CI combined, on the left. CI only on the right. Line is the probability scores

339 generated by logistic regression and dots are the probability scores generated by sliding

340 window methods. A-T- amyloid negative and tau negative; $A + T_{None/MTL}$ amyloid positive

341 and tau negative or amyloid positive with tau uptake limited to medial temporal region;

342 $A+T_{MOD}+$ amyloid positive with moderate tau uptake in temporo-parietal region; $A+T_{HIGH}+$

343 amyloid positive with high tau uptake in temporo-parietal region.

344 Discussion

- In the present study, we evaluated the ability of plasma p217+tau to discriminate between AD
- 346 disease stages, employing the biological PET stages recommended by draft NIA-AA Revised
- 347 Criteria 2023 ⁹ where we have defined the Advanced stage as >80 Centaur (2.68 SUVR_{temporo-}
- 348 _{parietal}). We showed that as disease progressed from A-T- to the Advanced biological PET
- 349 stages (A+T_{HIGH}+), there was a clear incremental trend in plasma p217+tau concentration,
- 350 with A+T- or A+T_{MTL}+ experiencing an almost two-fold increase, A+T_{MOD}+ more than a
- 351 three-fold increase, and $A+T_{HIGH}+$ more than a five-fold increase in p217+tau, relative to A-
- 352 T-.
- 353 Next, our group-level analysis was performed with a clinical trial in mind, where establishing
- 354 cut-off points allowed screening individuals at certain disease stages in or out of the trial or
- 355 enabled grouping enrolled participants for analytical purposes. This is critical as clinical trials
- move to recruit participants based on not merely $A\beta$ or tau positive or negative status, but
- enroll based on magnitude and topographical distribution of A β and tau (such as
- 358 TRAILBLAZER-ALZ 2¹). With high cost and limited availability of PET, predicting level
- and spatiotemporal patterns of AD pathology, particularly for tau, using plasma biomarkersbecomes a priority.
- 361 Group-level examination of how well plasma p-tau217 can distinguish between different
- 362 Braak-like PET stages in CU has been reported in a recent study by Jack *et al.* ²³. They found
- that p-tau217 discriminated between tau PET negative and tau PET positive (any Braak-like
- 364 PET stage) with an AUC of 0.83 which was not significantly different from the
- 365 discrimination by Quanterix p-tau181 or a base model including age, sex and APOE. Only
- 366 37% of our CU were A+, and among these, only a few had high neocortical tau burden, so
- 367 our study lacked the statistical power to discriminate between AD biological PET stages
- 368 within the CU group. Thus, we chose to limit our report to either the CU & CI combined
- 369 group or CI-only group.
- 370 Here, we showed that if screening for participants with early symptomatic AD, with $A\beta$ and
- 371 intermediate/high neocortical tau (similar to TRAILBLAZER-ALZ 2), plasma p217+tau
- 372 could discriminate between participants at these stages and other CI participants with an
- AUC of 0.89, and if the Youden threshold derived in this cohort for this purpose of 177.4
- fg/ml was used, 94% of p217+tau positive participants would be in the target PET stages
- 375 (Intermediate/Advanced: $A+T_{MOD}+$ or $A+T_{HIGH}+$). However, when investigating the utility of
- plasma p217+tau for separating advanced (A+T_{HIGH}+) stage of AD in the participants above

the p217+tau threshold of 177.4 fg/ml, the AUC was lower (0.75) and the Youden threshold

- 378 gave a NPV of 0.84 with a PPV of only 0.51. Tau PET scan would still be essential for
- 379 separating A+T_{MOD}+ from A+T_{HIGH}+.
- 380 Alternatively, if a trial were to enrol symptomatic participants but exclude those with
- 381 Advanced stage AD (A+T_{HIGH}+), we showed that 95% of CI participants with plasma
- $p_{217}+tau < 230.3 \text{ fg/ml}$ were in disease stages lower than $A+T_{HIGH}+$ and therefore this
- 383 threshold could be appropriate for exclusion of A+T_{HIGH}+.
- 384 The pairwise discrimination of each pair of AD biological PET stages —Initial vs. Early,
- 385 Early vs. Intermediate, and Intermediate vs. High—yielded lower AUC values. The AUC of
- 386 0.64 for Initial *vs*. Early, suggested that p217+tau did not have adequate discriminatory
- 387 performance for these two stages and provided additional support for combining these two
- into one stage for subsequent analyses. The AUC of 0.76, observed in the discrimination
- between Early and Intermediate stages, falls within an acceptable yet relatively lower range.
- 390 This highlights that the higher AUC of 0.92 reported for the A-T-/Initial/Early vs.
- 391 Intermediate/Advanced discrimination is predominantly influenced by the inclusion of more
- 392 extreme values from A-T- and Advanced stages in the discrimination. The same reasoning
- 393 applies to the AUC of 0.77 for Intermediate vs. High relative to the AUC of 0.91 for A-T-
- 394 /Initial/Early/Intermediate vs. Advanced.
- 395 Previous studies have shown that ¹⁸F-MK6240 might be better suited to detect early tau
- 396 accumulation (Me ROI) compared to ¹⁸F-Flortaucipir ^{24, 25}, thus our use of ¹⁸F-MK6240 as
- 397 tau PET tracer (as compared to Flortaucipir in the study by Jack *et al.*) may have provided a
- 398 more optimal identification of Early stage AD. Yet our findings with ¹⁸F-MK6240 were not
- 399 able to show that plasma p217+tau was able to discriminate A+T- from A+T_{MTL}+.
- 400 In a patient-centric approach, an individual's absolute risk of having AD pathology at a given
- 401 plasma biomarker concentration may be more relevant for clinical decision-making.
- 402 Therefore, we developed a risk prediction model using p217+tau as the predictor and
- 403 estimated probability scores —which are individuals' absolute risk— of falling within a
- 404 disease stage for their individual p217+tau level. The plot of the likelihood of PET stage *vs*.
- 405 p217+tau concentration showed good discrimination of A-T- vs any A+ stage and of
- 406 combined Intermediate/Advanced disease stage vs lower stages in the CI. However, with the
- 407 overlap in likelihood functions for most PET stages, confident staging of an individual with
- 408 plasma p217+tau alone is limited. One instead should consider an individual participant's

- 409 likelihood for belonging to each of the stages based on their p217+tau level as illustrated by
- 410 Figure 3.
- 411 A limitation of this study is that the findings are derived from a research cohort with a
- 412 relatively high prevalence of A β -PET positivity in the three clinical groups. Replication of
- 413 prevalence-dependent findings (i.e., PPV, NPV, estimated probability scores) in a "real-
- 414 world" memory clinic setting is needed before any of the findings could be applied in clinical
- 415 practice. Moreover, future studies are needed to develop risk prediction models using a
- 416 combination of several factors to accurately predict individual-level disease stages.
- 417 To conclude, plasma p217+tau performs well for group-level discrimination between disease
- 418 stages (except Initial and Early), a useful property for clinical trial screening and enrichment.

419 Acknowledgments

- 420 Some data used in this research article were obtained from the Australian Imaging Biomarkers
- 421 and Lifestyle flagship study of aging (AIBL), funded by the Commonwealth Scientific and
- 422 Industrial Research Organization (CSIRO), National Health and Medical Research Council
- 423 (NHMRC), and other participating institutions. Some data were obtained from the Australian
- 424 Dementia Network (ADNeT) that receives funding support from the NHMRC. AIBL
- 425 researchers are listed on the website www.aibl.csiro.au. The authors thank those who
- 426 participated in the study, as well as their families.

427 Funding

428 The research was supported by the Australian Federal Government through NHMRC grants 429 APP1132604, APP1140853 and APP1152623 and by a grant from Enigma Australia. Janssen 430 Pharmaceuticals paid a commercial data access fee to the AIBL study of ageing. Janssen 431 Pharmaceuticals performed the p217+tau measurements but did not perform the data analysis. The co-authors employed by Janssen did provide comments on the manuscript and Janssen 432 433 provided approval for submission of the manuscript. The other sponsors had no role in the 434 design and conduct of the study, in the collection, analysis, and interpretation of data, or in the 435 preparation of the manuscript.

436 Competing interests

- 437 Christopher C. Rowe has received research grants from NHMRC, Enigma Australia, Biogen,
- 438 Eisai and Abbvie. He is on the scientific advisory board for Cerveau Technologies and has
- 439 consulted for Prothena, Eisai, Roche, and Biogen Australia. Victor L. Villemagne is and has
- 440 been a consultant or paid speaker at sponsored conference sessions for Eli Lilly, Life Molecular
- 441 Imaging, GE Healthcare, IXICO, Abbvie, Lundbeck, Shanghai Green Valley Pharmaceutical
- 442 Co Ltd, AC Immune and Hoffmann La Roche. Ziad S. Saad, Gallen Triana-Baltzer, and
- 443 Hartmuth C. Kolb are employees of Janssen Pharmaceuticals. Simon M. Laws is a scientific
- 444 advisor for Cytox Ltd. The other authors did not report any conflict of interest.

References 445

446 447	1.	Sims JR, <i>et al.</i> Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. <i>JAMA</i> 330 , 512-527 (2023).
448 449	2.	Janelidze S, <i>et al.</i> Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. <i>Brain</i> 146 , 1592-1601 (2023).
450 451 452	3.	Groot C, <i>et al.</i> Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. <i>Alzheimers Res Ther</i> 14 , 67 (2022).
453 454 455	4.	Doré V, <i>et al.</i> Plasma p217+ tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer's continuum. <i>Alzheimers Dement: Diagn Assess Dis Monit</i> 14 , e12307 (2022).
456 457	5.	Feizpour A, <i>et al.</i> Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum. <i>J Prev Alzheimers Dis</i> 10 , 828-836 (2023).
458 459	6.	Jack CR, <i>et al.</i> Predicting amyloid PET and tau PET stages with plasma biomarkers. <i>Brain</i> 146 , 2029-2044 (2023).
460 461	7.	Therriault J, et al. Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nat Aging 2, 526-535 (2022).
462 463	8.	Rullmann M, et al. Multicenter 18F-PI-2620 PET for in vivo Braak staging of tau pathology in Alzheimer's disease. <i>Biomolecules</i> 12 , 458 (2022).
464 465	9.	NIA-AA. NIA-AA Revised Criteria for Alzheimer's Disease - AAIC 2023 DRAFT. (2023).
466 467 468 469	10.	Fowler C, <i>et al.</i> Fifteen years of the australian imaging, biomarkers and lifestyle (AIBL) study: progress and observations from 2,359 older adults spanning the spectrum from cognitive normality to Alzheimer's disease. <i>J Alzheimers Dis Rep</i> 5 , 443-468 (2021).
470 471 472 473	11.	McKhann GM, <i>et al.</i> The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimers Dement</i> 7 , 263-269 (2011).
474 475	12.	Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. <i>J Intern Med</i> 275 , 214-228 (2014).
476 477	13.	Bourgeat P, <i>et al.</i> Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiol Aging</i> 36 , S159-S166 (2015).
478 479	14.	Bourgeat P, <i>et al.</i> Implementing the centiloid transformation for 11C-PiB and β -amyloid 18F-PET tracers using CapAIBL. <i>Neuroimage</i> 183 , 387-393 (2018).
480 481	15.	Rowe CC, <i>et al.</i> Standardized expression of 18F-NAV4694 and 11C-PiB β-amyloid PET results with the Centiloid scale. <i>J Nucl Med</i> 57 , 1233-1237 (2016).
482 483	16.	Dore V, <i>et al.</i> Ic-P-167: automated reporting of tau PET quantification on brain surface. <i>Alzheimers Dement</i> 15 , P131-P132 (2019).
484 485 486	17.	Villemagne V, Dore V, Bourgeat P. The Tau MeTeR composites for the generation of continuous and categorical measures of tau deposits in the brain. <i>J Mol Med Ther</i> 1 , 25-32 (2017).

487		
488 489	18.	Doré V, <i>et al.</i> Relationship between amyloid and tau levels and its impact on tau spreading. <i>Eur J Nucl Med Mol Imaging</i> 48 , 2225-2232 (2021).
490 491	19.	Dore V, et al. A CenTauR scale based on 18F-MK6240. Alzheimer's Association International Conference, (2023).
492 493 494	20.	Villemagne VL, <i>et al.</i> CenTauR: Toward a universal scale and masks for standardizing tau imaging studies. <i>Alzheimers Dement: Diagn Assess Dis Monit</i> 15 , e12454 (2023).
495 496 497	21.	Triana-Baltzer G, <i>et al.</i> Development and validation of a high-sensitivity assay for measuring p217+ tau in plasma. <i>Alzheimers Dement: Diagn Assess Dis Monit</i> 13 , e12204 (2021).
498 499	22.	Krishnadas N, <i>et al.</i> Exploring discordant low amyloid beta and high neocortical tau positron emission tomography cases. <i>Alzheimers Dement (Amst)</i> 14 , e12326 (2022).
500 501	23.	Jack Jr CR, <i>et al.</i> Predicting amyloid PET and tau PET stages with plasma biomarkers. <i>Brain</i> 146 , 2029-2044 (2023).
502 503 504	24.	Bourgeat P, <i>et al.</i> Cross-Sectional and Longitudinal Comparison of Tau Imaging with 18F-MK6240 and 18F-Flortaucipir in Populations Matched for Age, MMSE and Brain Beta-Amyloid Burden. <i>J Prev Alzheimers Dis</i> 10 , 251-258 (2023).
505 506	25.	Gogola A, <i>et al.</i> Direct Comparison of the Tau PET Tracers (18)F-Flortaucipir and (18)F-MK-6240 in Human Subjects. <i>J Nucl Med</i> 63 , 108-116 (2022).
507 508		

508